Biomedicine and Chemical Sciences
2022, Volume 1, Issue 4 : 306-311 doi: https://doi.org/10.48112/bcs.v1i4.303
Research Article
Interleukin-6 Biomarker as Possible Predicator of Preeclampsia
Sajjad Kathem Ashour
 ,
Haider Abd Jabbar Al-Ammar
 ,
Yasmine Hamza Sharif
DOI : https://doi.org/10.48112/bcs.v1i4.303
Received
Aug. 24, 2022
Revised
Aug. 27, 2022
Accepted
Sept. 2, 2022
Published
Oct. 1, 2022
Abstract

Preeclampsia (PE) is a serious illness that can harm both mothers and unborn children and may even be fatal. It contributes significantly to maternal fatalities in underdeveloped countries. PE, which affects 2%–3% of women who are pregnant after 20 weeks of pregnancy, is marked by proteinuria and hypertension. PE is a significant condition that plays a significant role in maternal fatalities in underdeveloped countries and is a significant cause of death for both mothers and newborns. Each year, around 60,000 maternal fatalities occur in the world. Serum interleukin-6 (IL-6) was measured in pregnant women during the first trimester and second trimesters. IL-6 was necessary to establish serum biomarkers that can accurately predict the onset of preeclampsia. In a prospective cohort study that was conducted in the Obstetrics and Gynecology Department and Antenatal Care Unit at Maternity and Pediatrics Teaching Hospital in AL-Diwaniyah – Iraq, 160 pregnant patients between the years of 20 and 40 who were normotensive and had gestational ages of 10 to 13 weeks were included in this research between August 2021 and May 2022. Bioassays for IL-6 were conducted after blood samples were obtained. At the end of the study, it was confirmed that for women with pre-eclampsia (n = 33, 22.0%) and those women with no pre-eclampsia (n = 117, 78.0 %), there was no significant difference in the level between the preeclampsia and no preeclampsia group (p > 0.05).

Keywords
Preeclampsia
Interleukin-6
Hypertension
Pregnancy
REFERENCES
  1. Aggarwal, R., Jain, A. K., Mittal, P., Kohli, M., Jawanjal, P., & Rath, G. (2019). Association of pro‐and anti‐inflammatory cytokines in preeclampsia. Journal of Clinical Laboratory Analysis, 33(4), e22834. https://doi.org/10.1002/jcla.22834
  2. Bakrania, B. A., Hall, M. E., Shahul, S., & Granger, J. P. (2019). The Reduced Uterine Perfusion Pressure (RUPP) rat model of preeclampsia exhibits impaired systolic function and global longitudinal strain during pregnancy. Pregnancy Hypertension, 18, 169-172. https://doi.org/10.1016/j.preghy.2019.10.001
  3. Bakrania, B. A., Spradley, F. T., Drummond, H. A., LaMarca, B., Ryan, M. J., & Granger, J. P. (2020). Preeclampsia: linking placental ischemia with maternal endothelial and vascular dysfunction. Comprehensive Physiology, 11(1), 1315. https://doi.org/10.1002%2Fcphy.c200008
  4. Cornelius, D. C. (2018). Preeclampsia: from inflammation to immunoregulation. Clinical Medicine Insights: Blood Disorders, 11. https://doi.org/10.1177/1179545X17752325
  5. Cunningham, M. W., Amaral, L. M., Campbell, N. E., Cornelius, D. C., Ibrahim, T., Vaka, V. R., & LaMarca, B. (2021). Investigation of interleukin-2-mediated changes in blood pressure, fetal growth restriction, and innate immune activation in normal pregnant rats and in a preclinical rat model of preeclampsia. Biology of Sex Differences, 12(1), 1-10. https://doi.org/10.1186/s13293-020-00345-0
  6. Dechend, R., Lamarca, B., & Davidge, S. T. (2022). Salt, Aldosterone, and the Renin–Angiotensin System in Pregnancy. Chesley's Hypertensive Disorders in Pregnancy, 335-353. https://doi.org/10.1016/B978-0-12-818417-2.00010-5
  7. Gencheva, D., Nikolov, F., Uchikova, E., Mihaylov, R., Pencheva, B., & Vasileva, M. (2022). Interleukin-6 and its correlations with maternal characteristics and echocardiographic parameters in pre-eclampsia, gestational hypertension and normotensive pregnancy. Cardiovascular Journal of Africa, 33(2), 65-73. https://europepmc.org/article/pmc/pmc9364474
  8. Granger, J. P., Spradley, F. T., & Bakrania, B. A. (2018). The endothelin system: a critical player in the pathophysiology of preeclampsia. Current Hypertension Reports, 20(4), 1-8. https://doi.org/10.1007/s11906-018-0828-4
  9. Gronkowska, K. (2021). Aetiology, prophylaxis and management of preeclampsia. Acta Universitatis Lodziensis. Folia Biologica et Oecologica, 17, 111-121. https://doi.org/10.18778/1730-2366.16.22
  10. Gumusoglu, S. B., Chilukuri, A. S., Santillan, D. A., Santillan, M. K., & Stevens, H. E. (2020). Neurodevelopmental outcomes of prenatal preeclampsia exposure. Trends in Neurosciences, 43(4), 253-268. https://doi.org/10.1016/j.tins.2020.02.003
  11. Issotina Zibrila, A., Wang, Z., Ali, M. A., Osei, J. A., Sun, Y., Zafar, S., ... & Liu, J. (2021). Pyridostigmine ameliorates preeclamptic features in pregnant rats by inhibiting tumour necrosis factor-α synthetsis and antagonizing tumour necrosis factor-α-related effects. Journal of Hypertension, 39(9), 1774-1789. https://doi.org/10.1097/HJH.0000000000002932
  12. Ives, C. W., Sinkey, R., Rajapreyar, I., Tita, A. T., & Oparil, S. (2020). Preeclampsia—pathophysiology and clinical presentations: JACC state-of-the-art review. Journal of the American College of Cardiology, 76(14), 1690-1702. https://doi.org/10.1016/j.jacc.2020.08.014
  13. Jasovic Siveska, E. (2013). Preeclampsia: Should be Predict and Prevent?. Reprod Syst Sex Disord, 3(1). http://dx.doi.org/10.4172/2161-038X.1000e113
  14. Lamarca, B., Brewer, J., & Wallace, K. (2011). IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate?. International journal of interferon, cytokine and mediator research, 2011(3), 59–64. https://doi.org/10.2147/IJICMR.S16320
  15. Levine, R. J., Maynard, S. E., Qian, C., Lim, K. H., England, L. J., Yu, K. F., ... & Karumanchi, S. A. (2004). Circulating angiogenic factors and the risk of preeclampsia. New England Journal of Medicine, 350(7), 672-683. https://doi.org/10.1056/NEJMoa031884
  16. Mauro, A. K., Khurshid, N., Berdahl, D. M., Ampey, A. C., Adu, D., Shah, D. M., & Boeldt, D. S. (2021). Cytokine concentrations direct endothelial function in pregnancy and preeclampsia. Journal of Endocrinology, 248(2), 107-117. https://doi.org/10.1530/JOE-20-0397
  17. Nair, S., & Salomon, C. (2018, September). Extracellular vesicles and their immunomodulatory functions in pregnancy. In Seminars in immunopathology (Vol. 40, No. 5, pp. 425-437). Springer Berlin Heidelberg. https://doi.org/10.1007/s00281-018-0680-2
  18. Nakashima, A., Shima, T., Aoki, A., Kawaguchi, M., Yasuda, I., Tsuda, S., ... & Saito, S. (2021). Molecular and immunological developments in placentas. Human Immunology, 82(5), 317-324. https://doi.org/10.1016/j.humimm.2021.01.012
  19. Nawaz, M., & Verma, M. K. (2020). Evaluation of Differential Levels of Serum Interleukin-6 in Pre-Eclamptic and Normal Pregnancy Women. Chairman, Editorial Board, 8(1), 53.
  20. Negi, R., Haritha, V., Aziz, N., & Siddiqui, A. H. (2022). Biochemical markers in the pathogenesis of preeclampsia: novel link between placental growth factor and interleukin-6. Molecular and Cellular Biochemistry, 477(6), 1765-1774. https://doi.org/10.1007/s11010-022-04403-6
  21. Prairie, E., Côté, F., Tsakpinoglou, M., Mina, M., Quiniou, C., Leimert, K., ... & Chemtob, S. (2021). The determinant role of IL-6 in the establishment of inflammation leading to spontaneous preterm birth. Cytokine & Growth Factor Reviews, 59, 118-130. https://doi.org/10.1016/j.cytogfr.2020.12.004
  22. Raymond, D., & Peterson, E. (2011). A critical review of early-onset and late-onset preeclampsia. Obstetrical & Gynecological Survey, 66(8), 497-506. https://doi.org/10.1097/OGX.0b013e3182331028
  23. Sani, H. M., Vahed, S. Z., & Ardalan, M. (2019). Preeclampsia: a close look at renal dysfunction. Biomedicine & Pharmacotherapy, 109, 408-416. https://doi.org/10.1016/j.biopha.2018.10.082
  24. Setiawati, D. (2020). The Role of Inflammation in Pathogenesis of Preeclampsia: An Investigation of interleukin-6, interleukin 10, and the Ratio. International Journal of Medical Reviews and Case Reports, 4(10), 13-17. http://repositori.uin-alauddin.ac.id/id/eprint/20279
  25. Sircar, M., Thadhani, R., & Karumanchi, S. A. (2015). Pathogenesis of preeclampsia. Current opinion in nephrology and hypertension, 24(2), 131-138. https://doi.org/10.1097/MNH.0000000000000105
  26. Stepan, H., Hund, M., & Andraczek, T. (2020). Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome. Hypertension, 75(4), 918-926. https://doi.org/10.1161/HYPERTENSIONAHA.119.13763
  27. Trivedi, C. D., Trivedi, D. J., & Sagare, A. A. (2013). Oxidant and antioxidant imbalance as root cause in preeclampsia. Banaswini Publishing.
  28. Yagel, S., Cohen, S. M., & Goldman-Wohl, D. (2020). An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2020.10.023
Recommended Articles
Original Article Open Access
A FRAMEWORK OF MONOCLONAL ANTIBODIES AND RELATED PRODUCTION ENGINEERING
Navneet Kumar Verma
2025, Volume 4, Issue 4 : 26-34
Loading Image... Download PDF
Research Article Open Access
Investigation of Tritrichomonas Foetus in Cattle Using Different Methods in Basrah City – Iraq
Muntaha A. H. Nasir , 
Al-Idreesi S.R. , 
Wasfi A. Al-Masoudi
2023, Volume 2, Issue 1 : 39-43
DOI: https://doi.org/10.48112/bcs.v2i1.334
Loading Image... Download PDF
Research Article Open Access
The Role of Vitamin D and Zinc In Facing COVID-19 Injury
Yazi Abdullah Jassima
2022, Volume 1, Issue 1 : 6-10
DOI: https://doi.org/10.48112/bcs.v1i1.76
Loading Image... Download PDF
Research Article Open Access
Design and Synthesis Ligands Tetradents Substituted with Halogenes in α- Position and Conjugation with Riboflavin (Bioconjugates)
Nasser Thallaj
2022, Volume 1, Issue 2 : 47-56
DOI: https://doi.org/10.48112/bcs.v1i2.85
Loading Image... Download PDF
Biomedicine and Chemical Sciences journal thumbnail
Volume 1, Issue 4
Downloads
pdf Download PDF xml Download XML
Citations
2 Views
0 Downloads
Share this article
Share icon
Share on Facebook Share on LinkedIn
Share on Twitter
License
Copyright (c) Biomedicine and Chemical Sciences
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
Biomed. Chem. Sci. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Biomedicine and Chemical Sciences Logo
Biomedicine and Chemical Sciences
About Us
Biomedicine and Chemical Sciences (BCS), an international journal, publishes double blind peer-reviewed full-length, original papers, reviews or letters. BCS covers the latest developments in various fields of biomedicine such as cardiology, immunology, genetics, environmental health, neurology, oncology and toxicology
Support
visit www.bcsjournal.org
Follow Us
facebook twitter linkedin mendeley research-gate
© Copyright Biomedicine and Chemical Sciences (BCS). All Rights Reserved.